Literature DB >> 26424654

EBV and Autoimmunity.

Alberto Ascherio1,2,3, Kassandra L Munger4.   

Abstract

Although a role of EBV in autoimmunity is biologically plausible and evidence of altered immune responses to EBV is abundant in several autoimmune diseases, inference on causality requires the determination that disease risk is higher in individuals infected with EBV than in those uninfected and that in the latter it increases following EBV infection. This determination has so far been possible only for multiple sclerosis (MS) and, to some extent, for systemic lupus erythematosus (SLE), whereas evidence is either lacking or not supportive for other autoimmune conditions. In this chapter, we present the main epidemiological findings that justify the conclusion that EBV is a component cause of MS and SLE and possible mechanisms underlying these effects.

Entities:  

Keywords:  Autoimmunity; Epidemiology; Erythematosus; Multiple sclerosis; Risk factors; Systemic lupus

Mesh:

Year:  2015        PMID: 26424654     DOI: 10.1007/978-3-319-22822-8_15

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  46 in total

Review 1.  Lifestyle and Environmental Factors in Multiple Sclerosis.

Authors:  Lars Alfredsson; Tomas Olsson
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

Review 2.  Review of the "X chromosome-nucleolus nexus" hypothesis of autoimmune diseases with an update explaining disruption of the nucleolus.

Authors:  Wesley H Brooks
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 3.  Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.

Authors:  Tomas Olsson; Lisa F Barcellos; Lars Alfredsson
Journal:  Nat Rev Neurol       Date:  2016-12-09       Impact factor: 42.937

4.  Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3.

Authors:  Ryan Incrocci; Levi Barse; Amanda Stone; Sai Vagvala; Michael Montesano; Vijay Subramaniam; Michelle Swanson-Mungerson
Journal:  Virology       Date:  2016-10-25       Impact factor: 3.616

5.  Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.

Authors:  Emily C Leibovitch; Cheng-Te Major Lin; Bridgette J Billioux; Jennifer Graves; Emmanuelle Waubant; Steven Jacobson
Journal:  Mult Scler       Date:  2018-03-23       Impact factor: 6.312

6.  Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.

Authors:  David Baker; Samuel S Herrod; Cesar Alvarez-Gonzalez; Gavin Giovannoni; Klaus Schmierer
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

7.  HPV and systemic lupus erythematosus: a mosaic of potential crossreactions.

Authors:  Yahel Segal; Shani Dahan; Michele Calabrò; Darja Kanduc; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

8.  Increased risk of rheumatoid arthritis among mothers with children who carry DRB1 risk-associated alleles.

Authors:  Giovanna Ibeth Cruz; Xiaorong Shao; Hong Quach; Kimberly A Ho; Kirsten Sterba; Janelle A Noble; Nikolaos A Patsopoulos; Michael P Busch; Darrell J Triulzi; Wendy Sw Wong; Benjamin D Solomon; John E Niederhuber; Lindsey A Criswell; Lisa F Barcellos
Journal:  Ann Rheum Dis       Date:  2017-04-08       Impact factor: 19.103

9.  Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance.

Authors:  Jayaraju Dheekollu; Andreas Wiedmer; Kasirajan Ayyanathan; Julianna S Deakyne; Troy E Messick; Paul M Lieberman
Journal:  Cell       Date:  2021-01-21       Impact factor: 41.582

Review 10.  Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.

Authors:  Ya Cao; Longlong Xie; Feng Shi; Min Tang; Yueshuo Li; Jianmin Hu; Lin Zhao; Luqing Zhao; Xinfang Yu; Xiangjian Luo; Weihua Liao; Ann M Bode
Journal:  Signal Transduct Target Ther       Date:  2021-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.